Microbot Medical said its goal is to remove barriers to optimal care with the LIBERTY endovascular robotic system. | Source: Microbot Medical
Microbot Medical Inc., the developer of the LIBERTY Endovascular Robotic System, today said the Japanese Patent Office has granted the company its first patent in Japan. The patent covers the core LIBERTY technology, such as a compact robotic device for driving and manipulating the movement of at least one elongate surgical tool.
In addition, the Hingham, Mass.-based company has received patents in the U.S., China, and Israel over the past 90 days. It also earned 510(k) clearance from the U.S. Food and Drug Administration (FDA) for LIBERTY in September.
“Our initial focus is on the U.S. market. However, certain markets, such as Japan, represent attractive and strategically important markets for the LIBERTY System,” said Harel Gadot, chairman, president, and CEO of Microbot. “Building on our recent FDA clearance of LIBERTY, we are evaluating opportunities to expand into other global markets that have traditionally taken FDA clearance into consideration to potentially expedite local approval and adoption.”
Founded in 2010, Microbot Medical is focused on transforming endovascular procedures through advanced robotic technology.
LIBERTY promises precise, remote operation
LIBERTY is an endovascular robotic system for interventional physicians and hospitals seeking to improve procedural precision, safety, and efficiency, according to Microbot Medical. Unlike traditional manual techniques, it offers a single-use, compact design that enables controlled remote operation, the company claimed.
The surgical robot can be used in neurovascular, cardiovascular, and peripheral vascular procedures. Microbot added that LIBERTY could lower procedure costs and improve the overall quality of care.
In August, Microbot announced a new patent covering a modular robotic surgical system. The system includes a base and multiple tool-receiver units arranged as separate units. These units are independently and interchangeably attachable to the base. The company said the patent could allow it to adapt Liberty for a wider range of endovascular procedures.
Microbot Medical to raise $92M from stock sale
Microbot Medical last month said investors agreed to exercise outstanding preferred investment options, which could generate up to $92.2 million in gross proceeds. It intends to use the proceeds to support development, commercialization, and regulatory work for its LIBERTY system.
The company also plans to pursue potential acquisitions, expand applications of its intellectual property, and use the funding for working capital and general corporate purposes. Microbot said the latest developments have accelerated its commercial launch plans.
Surgical robotics will be on the agenda at RoboBusiness 2025, which takes place Oct. 15 and 16 in Santa Clara, Calif. Iman Jeddi, Ph.D. and senior vice president and general manager of Intuitive Surgical’s multiport platform, will offer a look inside the redesign and launch of the da Vinci 5, the company‘s next-generation surgical robotics system.
